UnknownPhase 4NCT02021825

Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders

Studying Neuromyelitis Optica

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Xuanwu Hospital, Beijing
Principal Investigator
Huiqing Dong, Doctor
Department of Neurology, Xuanwu Hospital, Capital Medical University
Intervention
Mitoxantrone(drug)
Enrollment
50 enrolled
Eligibility
18-55 years · All sexes
Timeline
20092015

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02021825 on ClinicalTrials.gov

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

See all trials for Neuromyelitis Optica

← Back to all trials